2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia

Biomaterials

Volumn 67, Issue , 2015, Pages 274-285

  Soldevilla, Mario Martinez ^a   Villanueva, Helena ^a   Bendandi, Maurizio ^b   Inoges, Susana ^c   López Díaz de Cerio, Ascensión ^c   Pastor, Fernando ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b ROSS UNIVERSITY SCHOOL OF MEDICINE   (Dominica)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Aptamer; Immunology; Lymphoma; Therapeutics

Indexed keywords

ANTIBODIES; ANTIGENS; CHEMOTHERAPY; DISEASES; IMMUNOLOGY; OLIGONUCLEOTIDES; ONCOLOGY; TUMORS;

ANTICANCER EFFECTS; ANTIGEN PRESENTING CELLS; APTAMERS; CANCER IMMUNOTHERAPY; DIFFERENT MECHANISMS; LYMPHOMA; THERAPEUTIC ANTIBODIES; THERAPEUTICS;

BONE;

2 FLUORO RNA OLIGONUCLEOTIDE APTAMER; ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; APTAMER; BETA CATENIN; CD40 LIGAND; SHORT HAIRPIN RNA; TELOMERASE; UNCLASSIFIED DRUG; CD40 ANTIGEN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; SMG1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; BONE MARROW; BONE MARROW APLASIA; BONE MARROW DERIVED DENDRITIC CELL; BRAIN TISSUE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL SURFACE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ACCUMULATION; DRUG ANTIGENICITY; FEASIBILITY STUDY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LYMPH NODE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; ANIMAL; CELL PROLIFERATION; DENDRITIC CELL; FLUORESCENCE; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR GENETICS; NONSENSE MEDIATED MRNA DECAY; NUCLEOTIDE SEQUENCE; PATHOLOGY; SURVIVAL ANALYSIS; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD40; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BONE MARROW; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; FLUORESCENCE; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MOLECULAR SEQUENCE DATA; NONSENSE MEDIATED MRNA DECAY; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; SELEX APTAMER TECHNIQUE; SURVIVAL ANALYSIS;

EID: 84939644741     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.07.020     Document Type: Article

References (47)

1. Ellington A.D., et al. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346(6287):818-822.
2. Tuerk C., et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 24(4):381-403.
3. Pastor F., et al. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol. Ther. 2011, 19(10):1878-1886.
4. Oney S., et al. Development of universal antidotes to control aptamer activity. Nat. Med. 2009, 15(10):1224-1228.
5. Gilboa E., et al. Use of oligonucleotide aptamer ligands to modulate the function of immune receptors. Clin. Cancer Res. 2013, 19(5):1054-1062.
6. Paulie S., et al. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol. Immunother. 1985, 20(1):23-28.
7. Clark E.A., et al. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. U. S. A. 1986, 83(12):4494-4498.
8. Foy T.M., et al. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med. 1994, 180(1):157-163.
9. Arpin C., et al. Generation of memory B cells and plasma cells in vitro. Science 1995, 268(5211):720-722.
10. DiSanto J.P., et al. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993, 361(6412):541-543.
11. van Kooten C., et al. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 1997, 9(3):330-337.
12. Maschmeyer G., et al. The epidemiology and treatment of infections in cancer patients. Int. J. Antimicrob. Agents 2008, 31(3):193-197.
13. Solanilla A., et al. CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells. Blood 2000, 95(12):3758-3764.
14. Stojakovic M., et al. CD154-stimulated GM-CSF release by vascular smooth muscle cells elicits monocyte activation-role in atherogenesis. J. Mol. Med. Berl. 2007, 85(11):1229-1238.
15. Vonderheide R.H., et al. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 2013, 19(5):1035-1043.
16. Zhou H.J., et al. Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood 2007, 110(6):2121-2127.
17. Travert M., et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J. Immunol. 2008, 181(2):1001-1011.
18. White A.L., et al. Fcgamma receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. J. Immunol. 2014, 193(4):1828-1835.
19. Inaba K., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176(6):1693-1702.
20. Pastor F., et al. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010, 465(7295):227-230.
21. Berezhnoy A., et al. Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing. Mol. Ther. 2012, 20(6):1242-1250.
22. Wong I., et al. A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(12):5428-5432.
23. Dollins C.M., et al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol. 2008, 15(7):675-682.
24. McNamara J.O., et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest. 2008, 118(1):376-386.
25. Pastor F., et al. CD28 aptamers as powerful immune response modulators. Mol. Ther. Nucleic Acids 2013, 2:e98. doi: 1038/mtna.2013.26.
26. Baccam M., et al. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP. J. Immunol. 2003, 170(6):3099-3108.
27. Ju Z., et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat. Med. 2007, 13(6):742-747.
28. Sekulovic S., et al. Prolonged self-renewal activity unmasks telomerase control of telomere homeostasis and function of mouse hematopoietic stem cells. Blood 2011, 118(7):1766-1773.
29. Ruiz-Herguido C., et al. Hematopoietic stem cell development requires transient Wnt/beta-catenin activity. J. Exp. Med. 2012, 209(8):1457-1468.
30. Kastan M.B., et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990, 75(10):1947-1950.
31. Castillo R., et al. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia 2000, 14(2):292-298.
32. Hicke B.J., et al. Tumor targeting by an aptamer. J. Nucl. Med. 2006, 47(4):668-678.
33. Usuki F., et al. Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts. Mol. Ther. 2006, 14(3):351-360.
34. Zhang J., et al. Intron function in the nonsense-mediated decay of beta-globin mRNA: indications that pre-mRNA splicing in the nucleus can influence mRNA translation in the cytoplasm. Rna 1998, 4(7):801-815.
35. de Vos S., et al. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J. Hematol. Oncol. 2014, 7(44). 10.1186/1756-8722-7-44.
36. Johnson P.W., et al. Clinical and biological effects of an agonist anti-CD40 antibody. A Cancer Research UK phase I study. Clin. Cancer Res. 2015, 21(6):1321-1328.
37. Vonderheide R.H., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 2007, 21(6):1321-1328.
38. Beatty G.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331(6024):1612-1616.
39. Gubin M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515(7528):577-5781.
40. Snyder A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371(23):2189-2199.
41. Yadav M., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515(7528):572-576.
42. Richman L.P., et al. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol. Res. 2014, 2(1):19-26.
43. Michel S., et al. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br. J. Cancer 2008, 99(11):1867-1873.
44. Casares N., et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J. Immunol. 2010, 185(9):5150-5159.
45. Gilboa E. Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay. Immunol. Res. 2013, 57(1-3):44-51.
46. Lindor N.M., et al. Concise handbook of familial cancer susceptibility syndromes - second edition. J. Natl. Cancer Inst. Monogr. 2008, 38:1-93.
47. Layzer J.M., et al. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides 2007, 17(1):1-11.